• Polycythemia vera (PV) is a rare myeloproliferative neoplasm that results in an abnormal increase in the number of blood cells.
• There is currently no curative treatment for PV and the principal goal is to reduce the hyperviscosity of the blood to prevent bleeding and clotting.
• This is managed through phlebotomy and, where required, through drug treatment in the form of aspirin or cytoreductive therapy: either hydroxyuria (HU), interferon or anagrelide.
• The most recent clinical guidelines for the management of PV are those issued in 2011 by the European LeukemiaNet. 1 • Response to cytoreductive therapy has been formally defined as haematocrit <45% without phlebotomy in addition to platelets ≤400x109/L, WBC ≤10x109/L, normal spleen size on imaging and no disease-related symptoms. 1 • The objective of the analysis was to assess the level of resistance/ intolerance to Hydroxyurea (HU) therapy in PV patients in the real world setting across Europe, based on the European LeukemiaNet (ELN) consensus paper.
• • Data for patients currently receiving HU therapy for more than 3 months were included in the analysis. For a patient to be classified as resistant/ intolerant they would have to fail one or more of the 4 elements (the need for phlebotomy, uncontrolled myeloproliferation, failure to reduce massive splenomegaly and presence of leg ulcers).
• Physicians were also asked to indicate their level of satisfaction with HU treatment for these patients on a 1-7 scale , where a score of 1 = not at all satisfied and a score of 7 = extremely satisfied. Where physicians indicated a strongly dissatisfied score (score of 1 or 2) they were asked for the reasons for their low level of satisfaction.
• 499 of the 969 patients (51%) were currently receiving HU for a period of more than 3 months. Highest use was recorded in Portugal (73%) and the lowest in Austria (38%).
• Demographic details are shown in Table 1 . Patients had been diagnosed for an average of 39.1 months, had a mean age of 68.5 years, and 58% were male.
• This analysis indicates that a proportion of patients continue to receive HU therapy despite being classified as resistant/ intolerant according to the ELN consensus paper and a lack of satisfaction among physicians.
• The data support the need for more drug options in later lines of therapy, for patients resistant/ intolerant to HU therapy. • Physicians reported that they were not completely satisfied with HU treatment (a score of 1-5) for 102 patients (51%) - Figure 2 . The most likely cause of dissatisfaction was inadequate response. 
(1)
Including: Platelet count • More than 400x 10(9)/L but less than or equal to 600x 10(9)/L OR • More than 600x 10(9)/L AND WBC count • More than 10x 10(9)/L but less than or equal to 15x 10(9)/L OR • More than 15x 10(9)/L
• Of the patients who had received HU therapy for more than 3 months, 200 patients (40%) were classified as resistant/intolerant to HU-therapy based on the 4 elements of the ELN guidelines. Of these, 139 patients (70%) were receiving phlebotomy on average 3.4 times in the past 6 months, 61 (31%) had uncontrolled myeloproliferation (platelet count greater than 400x 109/L and white blood cell count greater than 10x 109/L), 5 patients (3%) had ulcers and 1 (1%) had massive splenomegaly - Figure 1 . 
